Advertisement

Der Gastroenterologe

, Volume 13, Issue 3, pp 195–198 | Cite as

Immunsuppression nach Lebertransplantation

Optimale Therapie bei minimaler Nebenwirkung
  • D. Kroy
  • C. Trautwein
Schwerpunkt

Zusammenfassung

Die immunsuppressive Therapie nach Lebertransplantation ist keine exakt standardisierte, sondern vielmehr eine individuell auf jeden einzelnen Patienten abgestimmte medikamentöse Therapie zur Verhinderung einer Abstoßung, die das langfristige Transplantat- und Patientenleben ermöglichen soll. Sie berücksichtigt zum einen die Grunderkrankung, die zur Transplantation geführt hat, zum anderen aber auch koexistierende Erkrankungen und das individuelle Risikoprofil, das der Patient aufweist. Das Ziel, das bei allen Patienten gleichermaßen verfolgt wird, ist die optimale Therapie bei minimaler Nebenwirkung. Der folgende Artikel beschäftigt sich deshalb mit den zur Verfügung stehenden immunsuppressiven Substanzen, ihren Wirk- und Nebenwirkungsspektren und den daraus resultierenden möglichen Therapieregimes.

Schlüsselwörter

Organtransplantation Immunsuppressiva Kalzineurininhibitoren Antimetabolit mTOR-Inhibitor 

Immunosuppression after liver transplantation

Optimal therapy with minimal side effects

Abstract

Immunosuppressive therapy after liver transplantation is not exactly standardized, but is more an individually tailored medical treatment to achieve excellent long-term graft and patient survival. The therapy regimen takes into account the underlying etiology that led to the need for transplantation as well as concomitant diseases and the individual risk profile. The ultimate goal is to achieve optimal therapy with minimal side effects. The following article, therefore, presents the available immunosuppressive drugs, their respective modes of action as well as their side effects, and the resulting possible therapeutic regimens.

Keywords

Tissue transplantation Immunosuppressive agents Calcineurin inhibitors Antimetabolite mTOR inhibitor 

Notes

Einhaltung ethischer Richtlinien

Interessenkonflikt

D. Kroy und C. Trautwein geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Literatur

  1. 1.
    Adam R, Karam V, Delvart V et al (2015) Improved survival in liver transplant recipients receiving prolonged-release tacrolimus in the European Liver Transplant Registry. Am J Transplant 15:1267–1282CrossRefPubMedGoogle Scholar
  2. 2.
    Battelli C, Cho DC (2011) mTOR inhibitors in renal cell carcinoma. Therapy 8:359–367CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Beckebaum S, Iacob S, Sweid D et al (2011) Efficacy, safety, and immunosuppressant adherence in stable liver transplant patients converted from a twice-daily tacrolimus-based regimen to once-daily tacrolimus extended-release formulation. Transpl Int 24:666–675CrossRefPubMedGoogle Scholar
  4. 4.
    Bilbao I, Dopazo C, Castells L et al (2014) Immunosuppression based on everolimus in liver transplant recipients with severe early post-transplantation neurotoxicity. Transplant Proc 46:3104–3107CrossRefPubMedGoogle Scholar
  5. 5.
    Boudjema K, Camus C, Saliba F et al (2011) Reduced-dose tacrolimus with mycophenolate mofetil vs. standard-dose tacrolimus in liver transplantation: a randomized study. Am J Transplant 11:965–976CrossRefPubMedGoogle Scholar
  6. 6.
    Braun N, Dette S, Viebahn R (2003) Impairment of renal function following liver transplantation. Transplant Proc 35:1458–1460CrossRefPubMedGoogle Scholar
  7. 7.
    Cholongitas E (2017) Everolimus-based Immunosuppression in liver transplant recipients. Am J Transplant 17:2488CrossRefPubMedGoogle Scholar
  8. 8.
    Cholongitas E, Mamou C, Rodriguez-Castro KI et al (2014) Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review. Transpl Int 27:1039–1049CrossRefPubMedGoogle Scholar
  9. 9.
    De Simone P, Nevens F, De Carlis L et al (2012) Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial. Am J Transplant 12:3008–3020CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Herzer K, Strassburg CP, Braun F et al (2016) Selection and use of immunosuppressive therapies after liver transplantation: current German practice. Clin Transplant 30:487–501CrossRefPubMedGoogle Scholar
  11. 11.
    Jain A, Kashyap R, Marsh W et al (2001) Reasons for long-term use of steroid in primary adult liver transplantation under tacrolimus. Transplantation 71:1102–1106CrossRefPubMedGoogle Scholar
  12. 12.
    Kim JM, Kwon CH, Joh JW et al (2016) Conversion of once-daily extended-release tacrolimus is safe in stable liver transplant recipients: a randomized prospective study. Liver Transpl 22:209–216CrossRefPubMedGoogle Scholar
  13. 13.
    Kulke MH, Bendell J, Kvols L et al (2011) Evolving diagnostic and treatment strategies for pancreatic neuroendocrine tumors. J Hematol Oncol 4:29CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Lamattina JC, Mezrich JD, Fernandez LA et al (2013) Native kidney function following liver transplantation using calcineurin inhibitors: single-center analysis with 20 years of follow-up. Clin Transplant 27:193–202CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Lerut JP, Pinheiro RS, Lai Q et al (2014) Is minimal, [almost] steroid-free immunosuppression a safe approach in adult liver transplantation? Long-term outcome of a prospective, double blind, placebo-controlled, randomized, investigator-driven study. Ann Surg 260:886–891 (discussion 891–882)CrossRefPubMedGoogle Scholar
  16. 16.
    Lorho R, Hardwigsen J, Dumortier J et al (2011) Regression of new-onset diabetes mellitus after conversion from tacrolimus to cyclosporine in liver transplant patients: results of a pilot study. Clin Res Hepatol Gastroenterol 35:482–488CrossRefPubMedGoogle Scholar
  17. 17.
    Mcalister VC, Haddad E, Renouf E et al (2006) Cyclosporin versus tacrolimus as primary immunosuppressant after liver transplantation: a meta-analysis. Am J Transplant 6:1578–1585CrossRefPubMedGoogle Scholar
  18. 18.
    Moench C, Barreiros AP, Schuchmann M et al (2007) Tacrolimus monotherapy without steroids after liver transplantation – a prospective randomized double-blinded placebo-controlled trial. Am J Transplant 7:1616–1623CrossRefPubMedGoogle Scholar
  19. 19.
    Muduma G, Saunders R, Odeyemi I et al (2016) Systematic review and meta-analysis of tacrolimus versus ciclosporin as primary Immunosuppression after liver transplant. PLoS ONE 11:e160421CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Neuberger JM, Mamelok RD, Neuhaus P et al (2009) Delayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: the „ReSpECT“ study. Am J Transplant 9:327–336CrossRefPubMedGoogle Scholar
  21. 21.
    Razonable RR (2008) Cytomegalovirus infection after liver transplantation: current concepts and challenges. World J Gastroenterol 14:4849–4860CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Saliba F, De Simone P, Nevens F et al (2013) Renal function at two years in liver transplant patients receiving everolimus: results of a randomized, multicenter study. Am J Transplant 13:1734–1745CrossRefPubMedGoogle Scholar
  23. 23.
    Schena FP, Pascoe MD, Alberu J et al (2009) Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 87:233–242CrossRefPubMedGoogle Scholar
  24. 24.
    Schmeding M, Kiessling A, Neuhaus R et al (2011) Mycophenolate mofetil monotherapy in liver transplantation: 5‑year follow-up of a prospective randomized trial. Transplantation 92:923–929CrossRefPubMedGoogle Scholar
  25. 25.
    Stewart SF, Hudson M, Talbot D et al (2001) Mycophenolate mofetil monotherapy in liver transplantation. Lancet 357:609–610CrossRefPubMedGoogle Scholar
  26. 26.
    Teperman L, Moonka D, Sebastian A et al (2013) Calcineurin inhibitor-free mycophenolate mofetil/sirolimus maintenance in liver transplantation: the randomized spare-the-nephron trial. Liver Transpl 19:675–689CrossRefPubMedGoogle Scholar
  27. 27.
    Thimonier E, Guillaud O, Walter T et al (2014) Conversion to everolimus dramatically improves the prognosis of de novo malignancies after liver transplantation for alcoholic liver disease. Clin Transplant 28:1339–1348CrossRefPubMedGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2018

Authors and Affiliations

  1. 1.Klinik für Gastroenterologie, Stoffwechselkrankheiten und internistische IntensivmedizinRWTH Aachen UniklinikAachenDeutschland

Personalised recommendations